NSTL国家科技图书文献中心

1. A pharmacovigilance study of adverse events associated with polymyxins based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database NSTL国家科技图书文献中心

Wu, Tingxi | Shi, Yanfeng ... - 《Expert opinion on drug safety》 - 2025,24(1) - 69～77 - 共9页

摘要： and Drug Administration Adverse Event Reporting | and compare potential adverse events (AEs) between | System between 2004 and 2022. Potential signals were | estimated by the reporting* odds ratio (ROR), and subgroup* | colistin and* polymyxin B (PMB).MethodsOutpatient*

关键词： Polymyxins | FAERS | reporting odds ratios | nephrotoxicity | neurotoxicity

2. Post-marketing safety surveillance of ado-trastuzumab emtansine: a real-world data retrospective cohort study using disproportionality analysis NSTL国家科技图书文献中心

Chen, Endong | Gan, Yaowei ... - 《Expert opinion on drug safety》 - 2025,24(5) - 565～576 - 共12页

摘要：%), and nervous system (14.55%). Hemorrhagic adverse | . Although several adverse* events (AEs) have been reported* | its safety profile.Research design and* methodsTo* | associated AEs, we employed the reporting* odds ratio (ROR* | ), the proportional reporting* ratio (PRR), the Bayesian*

关键词： FAERS, US food and drug administration adverse events reporting system | HER2-positive breast cancer | ado-trastuzumab emtansine | disproportionality analysis | adverse events | thrombocytopenia | hemorrhage

3. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin NSTL国家科技图书文献中心

Xu, Zhongliang | Huang, Dan ... - 《Expert opinion on drug safety》 - 2025,24(1) - 49～57 - 共9页

摘要： antibody-drug conjugate approved by the US Food and Drug | FDA Adverse Event Reporting System (FAERS | lymphoma. This study evaluated adverse* events (AEs* | FAERS database, and 1,388 reports of polatuzumab | Administration (FDA) for patients with diffuse large B-cell

关键词： Polatuzumab vedotin | adverse event | FAERS | pharmacovigilance | data mining

4. A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant NSTL国家科技图书文献中心

Wen, Heli | Ding, Yitian ... - 《Expert opinion on drug safety》 - 2025,24(6) - 745～752 - 共8页

摘要： Food and Drug Administration Adverse Event Reporting | , dizziness and* fatigue. Unexpected adverse events such as* | System (FAERS) database. Four algorithms (ROR, PRR | signals of atogepant-associated adverse* events (AEs) in* | the majority of adverse* events (AEs), with a notable*

关键词： Adverse event | data mining | FAERS | pharmacovigilance | atogepant

5. Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database NSTL国家科技图书文献中心

Sun, Yu | Xu, Tao ... - 《Expert opinion on drug safety》 - 2025,24(2) - 233～239 - 共7页

摘要： Administration Adverse Event Reporting System (FAERS) for this | abrocitinib-associated AEs, we used the US Food and Drug | adverse events (AEs) associated with abrocitinib in a | ) modulates cytokines involved in AD pathophysiology, and | investigated as the primary suspected from the FAERS* to*

关键词： Abrocitinib | FAERS | adverse events | signal detection | pharmacovigilance

6. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System NSTL国家科技图书文献中心

Barbieri, Maria Anto... | Russo, Giulia ... - 《European journal of clinical pharmacology》 - 2025,81(5) - 755～770 - 共16页

摘要： and Drug Administration Adverse Event Reporting | , teclistamab, and talquetamab) were analyzed in the US Food | %) linked to CV and* respiratory adverse events, primarily | adverse events* (AEs). This study aims to identify | System (FAERS) database. Descriptive analysis was

关键词： Cardiovascular toxicity | Disproportionality analysis | FAERS | Monoclonal antibodies | Multiple myeloma | Respiratory toxicity

7. Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan NSTL国家科技图书文献中心

Rikuto Masuda | Yoshihiro Noguchi ... - 《Oncology》 - 2025,103(2) - 134～142 - 共9页

摘要： of ARPI and cardiovascular events using the US Food | and Drug Administration (FDA) Adverse Event | Reporting System (FAERS) has been reported; however, the | cardiovascular death and* all cardiovascular events as the* | primary endpoints, and major cardiovascular events

关键词： Androgen receptor pathway inhibitors; Cardiovascular adverse events; Medical institution

8. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system NSTL国家科技图书文献中心

Xia, Chunyong | Liu, Zhijing ... - 《Investigational new drugs.》 - 2024,42(5) - 500～509 - 共10页

摘要： and Drug Administration Adverse Event Reporting | events (AEs) associated with relugolix from the US Food | System (FAERS). Methods: Disproportionality analysis | advanced prostate cancer. This study assessed adverse | , including the reporting* odds ratio (ROR), the proportional*

关键词： Efficacy | Safety | Relugolix | Prostate cancer | Adverse events | FAERS

9. Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and?systemic symptoms: a disproportionality analysis NSTL国家科技图书文献中心

Wanshu,Li | Yanan,Yu ... - 《International journal of clinical pharmacy.》 - 2024,46(6) - 1381～1390 - 共10页

摘要： the US Food and Drug Administration Adverse Events | Reporting System (FAERS) database.Method A retrospective | were used to identify adverse events in the FAERS | of a correlation between PPIs and* drug reactions* | gastrointestinal hemorrhage, eradicating Helicobacter pylori, and

关键词： Disproportionality analysis | Drug reaction with eosinophilia systemic symptoms (DRESS) | FAERS | Proton pump inhibitors

10. Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event (FAERS) NSTL国家科技图书文献中心

Al-Yafeai, Zaki | Sondhi, Manush ... - 《International Journal of Cardiology》 - 2024,402 - 131819～131819 - 共6页

摘要：. The US Food* and Drug Administration (FDA) has* | study utilized the FDA Adverse Event Reporting System | (FAERS) database to analyze adverse* events associated* | , which contained >25 million adverse* events, a total of* | therapeutic agents for psoriasis. Cardiac adverse events

摘要： and Drug Administration Adverse Event Reporting | and compare potential adverse events (AEs) between | System between 2004 and 2022. Potential signals were | estimated by the reporting* odds ratio (ROR), and subgroup* | colistin and* polymyxin B (PMB).MethodsOutpatient*

关键词： Polymyxins | FAERS | reporting odds ratios | nephrotoxicity | neurotoxicity

摘要：%), and nervous system (14.55%). Hemorrhagic adverse | . Although several adverse* events (AEs) have been reported* | its safety profile.Research design and* methodsTo* | associated AEs, we employed the reporting* odds ratio (ROR* | ), the proportional reporting* ratio (PRR), the Bayesian*

关键词： FAERS, US food and drug administration adverse events reporting system | HER2-positive breast cancer | ado-trastuzumab emtansine | disproportionality analysis | adverse events | thrombocytopenia | hemorrhage

摘要： antibody-drug conjugate approved by the US Food and Drug | FDA Adverse Event Reporting System (FAERS | lymphoma. This study evaluated adverse* events (AEs* | FAERS database, and 1,388 reports of polatuzumab | Administration (FDA) for patients with diffuse large B-cell

关键词： Polatuzumab vedotin | adverse event | FAERS | pharmacovigilance | data mining

摘要： Food and Drug Administration Adverse Event Reporting | , dizziness and* fatigue. Unexpected adverse events such as* | System (FAERS) database. Four algorithms (ROR, PRR | signals of atogepant-associated adverse* events (AEs) in* | the majority of adverse* events (AEs), with a notable*

关键词： Adverse event | data mining | FAERS | pharmacovigilance | atogepant

关键词： Abrocitinib | FAERS | adverse events | signal detection | pharmacovigilance

摘要： and Drug Administration Adverse Event Reporting | , teclistamab, and talquetamab) were analyzed in the US Food | %) linked to CV and* respiratory adverse events, primarily | adverse events* (AEs). This study aims to identify | System (FAERS) database. Descriptive analysis was

关键词： Cardiovascular toxicity | Disproportionality analysis | FAERS | Monoclonal antibodies | Multiple myeloma | Respiratory toxicity

摘要： of ARPI and cardiovascular events using the US Food | and Drug Administration (FDA) Adverse Event | Reporting System (FAERS) has been reported; however, the | cardiovascular death and* all cardiovascular events as the* | primary endpoints, and major cardiovascular events

关键词： Androgen receptor pathway inhibitors; Cardiovascular adverse events; Medical institution

摘要： and Drug Administration Adverse Event Reporting | events (AEs) associated with relugolix from the US Food | System (FAERS). Methods: Disproportionality analysis | advanced prostate cancer. This study assessed adverse | , including the reporting* odds ratio (ROR), the proportional*

关键词： Efficacy | Safety | Relugolix | Prostate cancer | Adverse events | FAERS

摘要： the US Food and Drug Administration Adverse Events | Reporting System (FAERS) database.Method A retrospective | were used to identify adverse events in the FAERS | of a correlation between PPIs and* drug reactions* | gastrointestinal hemorrhage, eradicating Helicobacter pylori, and

关键词： Disproportionality analysis | Drug reaction with eosinophilia systemic symptoms (DRESS) | FAERS | Proton pump inhibitors

摘要：. The US Food* and Drug Administration (FDA) has* | study utilized the FDA Adverse Event Reporting System | (FAERS) database to analyze adverse* events associated* | , which contained >25 million adverse* events, a total of* | therapeutic agents for psoriasis. Cardiac adverse events

关键词： CAD | Psoriasis | AF | Pericarditis

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： and Drug Administration Adverse Event Reporting | and compare potential adverse events (AEs) between | System between 2004 and 2022. Potential signals were | estimated by the reporting odds ratio (ROR), and subgroup | colistin and polymyxin B (PMB).MethodsOutpatient

关键词： Polymyxins | FAERS | reporting odds ratios | nephrotoxicity | neurotoxicity

摘要：%), and nervous system (14.55%). Hemorrhagic adverse | . Although several adverse events (AEs) have been reported | its safety profile.Research design and methodsTo | associated AEs, we employed the reporting odds ratio (ROR | ), the proportional reporting ratio (PRR), the Bayesian

关键词： FAERS, US food and drug administration adverse events reporting system | HER2-positive breast cancer | ado-trastuzumab emtansine | disproportionality analysis | adverse events | thrombocytopenia | hemorrhage

摘要： antibody-drug conjugate approved by the US Food and Drug | FDA Adverse Event Reporting System (FAERS | lymphoma. This study evaluated adverse events (AEs | FAERS database, and 1,388 reports of polatuzumab | Administration (FDA) for patients with diffuse large B-cell

关键词： Polatuzumab vedotin | adverse event | FAERS | pharmacovigilance | data mining

摘要： Food and Drug Administration Adverse Event Reporting | , dizziness and fatigue. Unexpected adverse events such as | System (FAERS) database. Four algorithms (ROR, PRR | signals of atogepant-associated adverse events (AEs) in | the majority of adverse events (AEs), with a notable

关键词： Adverse event | data mining | FAERS | pharmacovigilance | atogepant

关键词： Abrocitinib | FAERS | adverse events | signal detection | pharmacovigilance

摘要： and Drug Administration Adverse Event Reporting | , teclistamab, and talquetamab) were analyzed in the US Food | %) linked to CV and respiratory adverse events, primarily | adverse events (AEs). This study aims to identify | System (FAERS) database. Descriptive analysis was

关键词： Cardiovascular toxicity | Disproportionality analysis | FAERS | Monoclonal antibodies | Multiple myeloma | Respiratory toxicity

摘要： of ARPI and cardiovascular events using the US Food | and Drug Administration (FDA) Adverse Event | Reporting System (FAERS) has been reported; however, the | cardiovascular death and all cardiovascular events as the | primary endpoints, and major cardiovascular events

关键词： Androgen receptor pathway inhibitors; Cardiovascular adverse events; Medical institution

摘要： and Drug Administration Adverse Event Reporting | events (AEs) associated with relugolix from the US Food | System (FAERS). Methods: Disproportionality analysis | advanced prostate cancer. This study assessed adverse | , including the reporting odds ratio (ROR), the proportional

关键词： Efficacy | Safety | Relugolix | Prostate cancer | Adverse events | FAERS

摘要： the US Food and Drug Administration Adverse Events | Reporting System (FAERS) database.Method A retrospective | were used to identify adverse events in the FAERS | of a correlation between PPIs and drug reactions | gastrointestinal hemorrhage, eradicating Helicobacter pylori, and

关键词： Disproportionality analysis | Drug reaction with eosinophilia systemic symptoms (DRESS) | FAERS | Proton pump inhibitors

摘要：. The US Food and Drug Administration (FDA) has | study utilized the FDA Adverse Event Reporting System | (FAERS) database to analyze adverse events associated | , which contained >25 million adverse events, a total of | therapeutic agents for psoriasis. Cardiac adverse events

关键词： CAD | Psoriasis | AF | Pericarditis

4008-161-200 800-990-8900

国家科技图书文献中心

摘要： and Drug Administration Adverse Event Reporting | and compare potential adverse events (AEs) between | System between 2004 and 2022. Potential signals were | estimated by the reporting* odds ratio (ROR), and subgroup* | colistin and* polymyxin B (PMB).MethodsOutpatient*

摘要：%), and nervous system (14.55%). Hemorrhagic adverse | . Although several adverse* events (AEs) have been reported* | its safety profile.Research design and* methodsTo* | associated AEs, we employed the reporting* odds ratio (ROR* | ), the proportional reporting* ratio (PRR), the Bayesian*

摘要： antibody-drug conjugate approved by the US Food and Drug | FDA Adverse Event Reporting System (FAERS | lymphoma. This study evaluated adverse* events (AEs* | FAERS database, and 1,388 reports of polatuzumab | Administration (FDA) for patients with diffuse large B-cell

摘要： Food and Drug Administration Adverse Event Reporting | , dizziness and* fatigue. Unexpected adverse events such as* | System (FAERS) database. Four algorithms (ROR, PRR | signals of atogepant-associated adverse* events (AEs) in* | the majority of adverse* events (AEs), with a notable*

摘要： and Drug Administration Adverse Event Reporting | , teclistamab, and talquetamab) were analyzed in the US Food | %) linked to CV and* respiratory adverse events, primarily | adverse events* (AEs). This study aims to identify | System (FAERS) database. Descriptive analysis was

摘要： of ARPI and cardiovascular events using the US Food | and Drug Administration (FDA) Adverse Event | Reporting System (FAERS) has been reported; however, the | cardiovascular death and* all cardiovascular events as the* | primary endpoints, and major cardiovascular events

摘要： and Drug Administration Adverse Event Reporting | events (AEs) associated with relugolix from the US Food | System (FAERS). Methods: Disproportionality analysis | advanced prostate cancer. This study assessed adverse | , including the reporting* odds ratio (ROR), the proportional*

摘要： the US Food and Drug Administration Adverse Events | Reporting System (FAERS) database.Method A retrospective | were used to identify adverse events in the FAERS | of a correlation between PPIs and* drug reactions* | gastrointestinal hemorrhage, eradicating Helicobacter pylori, and

摘要：. The US Food* and Drug Administration (FDA) has* | study utilized the FDA Adverse Event Reporting System | (FAERS) database to analyze adverse* events associated* | , which contained >25 million adverse* events, a total of* | therapeutic agents for psoriasis. Cardiac adverse events